ReOx Ltd
ReOx is a drug discovery company that is building on the primary research of the founding academics to develop novel treatments for disease by controlling the activity of hypoxia inducible factor (HIF). The company's world-leading technology is based on biological and medical understanding from Professors Peter Ratcliffe, Patrick Maxwell and Chris Pugh (from the Wellcome Trust Centre for Human Genetics) of the enzymes that regulate HIF, combined with the expertise of Professor Christopher Schofield at the Department of Chemistry in molecular inhibitors of these enzymes.
Contact
Sarah Hargreaves
ReOx Ltd
E: sarah.hargreaves@reox.co.uk